Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549892 | 0.90 | AGTR1 (0.44) | AGTR1MMP13AGTR2CES2TP53 | |
| SCHEMBL17670339 | 0.87 | AGTR1 (0.42) | AGTR1MEN1KMT2AAGTR2BRS3 | |
| SCHEMBL17670499 | 0.86 | MMP13 (0.40) | AGTR1MMP13MEN1KMT2AAGTR2 | |
| SCHEMBL17544469 | 0.86 | AGTR1 (0.41) | AGTR1MMP13AGTR2CES2TP53 | |
| SCHEMBL17670462 | 0.86 | AGTR1 (0.40) | AGTR1MMP13AGTR2CES2PTGER4 | |
| SCHEMBL17544961 | 0.86 | MMP13 (0.38) | AGTR1MMP13MEN1KMT2AAGTR2 | |
| SCHEMBL17670473 | 0.85 | AGTR1 (0.41) | AGTR1MMP13AGTR2TP53 | |
| SCHEMBL17670424 | 0.85 | AGTR1 (0.43) | AGTR1MEN1KMT2AAGTR2BRS3 | |
| SCHEMBL17549916 | 0.85 | MMP13 (0.39) | AGTR1MMP13AGTR2CES2PTGER4 | |
| SCHEMBL17670350 | 0.84 | MMP13 (0.38) | AGTR1MMP13AGTR2CES2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | AGTR1 2794/4885MMP13 397/4885MEN1 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.